The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of poly ADP ribose polymerase (PARP) inhibitors on clonal hematopoiesis.
 
Kelly L Bolton
Research Funding - GRAIL
 
Lea Anne Moukarzel
No Relationships to Disclose
 
Ryan Ptashkin
No Relationships to Disclose
 
Teng Gao
No Relationships to Disclose
 
Minal Patel
No Relationships to Disclose
 
Nicole Caltabellotta
No Relationships to Disclose
 
Lior Zvi Braunstein
No Relationships to Disclose
 
Carol Aghajanian
Consulting or Advisory Role - Clovis Oncology; Eisai; Immunogen; Mersana; Roche; Tesaro
Research Funding - Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst)
 
David Michael Hyman
Employment - Lilly; Loxo
Stock and Other Ownership Interests - Fount Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Fount Therapeutics; Genentech; Lilly; Pfizer
Research Funding - AstraZeneca; Bayer; Loxo; Puma Biotechnology
Travel, Accommodations, Expenses - Chugai Pharma; Genentech
 
Michael F. Berger
Consulting or Advisory Role - Roche
Research Funding - Grail
 
Luis A. Diaz
Leadership - Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Amgen (I); Jounce Therapeutics; Neophore; PapGene, Inc.; Personal Genome Diagnostics; Thrive Earlier Detection Corp; Zydecom
Consulting or Advisory Role - Caris Life Sciences; Cell Design Labs; Genocea Biosciences; Lyndra Therapeutics; Merck; Neophore; Personal Genome Diagnostics; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Travel, Accommodations, Expenses - Merck
 
Bob T. Li
Consulting or Advisory Role - Guardant Health; Hengrui Therapeutics
Research Funding - Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); GRAIL (Inst); Guardant Health (Inst); Hengrui Therapeutics (Inst); Lilly (Inst); MORE Health (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - US62/514,661 (Inst); US62/685,057 (Inst)
 
Wassim Abida
Honoraria - CARET
Consulting or Advisory Role - Clovis Oncology; Daiichi Sankyo; Janssen; MORE Health; ORIC Pharmaceuticals
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Clovis Oncology; GlaxoSmithKline; ORIC Pharmaceuticals
 
Alison M. Schram
No Relationships to Disclose
 
Britta Weigelt
Consulting or Advisory Role - Genentech/Roche (I); Goldman Sachs (I); Invicro (I); PAIGE (I); Repare Therapeutics (I); Repare Therapeutics (I); Ventana Medical Systems (I); Volition RX (I)
 
Claire Frances Friedman
Consulting or Advisory Role - AstraZeneca/MedImmune
Research Funding - Arcus Biosciences (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst)
Other Relationship - Guidepoint Global
(OPTIONAL) Uncompensated Relationships - Genentech; Merck
 
Ahmet Zehir
Honoraria - Illumina
 
Elli Papaemmanuil
No Relationships to Disclose
 
Karen Anne Cadoo
Honoraria - OncLive
Consulting or Advisory Role - GlaxoSmithKline/Tesaro
Research Funding - AstraZeneca (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Ross L. Levine
Leadership - Qiagen
Stock and Other Ownership Interests - C4 Therapeutics; Imago Pharma; IsoPlexis; Loxo; Qiagen
Honoraria - Amgen; Lilly
Consulting or Advisory Role - C4 Therapeutics; Celgene; Imago Pharma; IsoPlexis; Loxo; Prelude Therapeutics; Roche
Speakers' Bureau - Amgen; Lilly
Research Funding - Celgene; Prelude Therapeutics; Roche
Travel, Accommodations, Expenses - Auron Therapeutics; C4 Therapeutics; Constellation Pharmaceuticals; Genome; Incyte; Qiagen